Learn what cell and gene therapy is, how it differs from conventional medicine, and why it's creating a new turning point in how we treat disease.
Working together. Learning together. Thriving together. Discover how you can join us in changing people's lives. Join us Novartis in Society Integrated Report 2024 Read more about our performance against our business, environmental, social and governance (ESG) priorities in the Novartis in Societ...
Novartis Gene Therapies Manufacturing Quality Audit program Novartis quality management system (QMS) Product and patient safety training Regulatory inspections Product recalls Third-party suppliers Novartis and the European Union (EU) Awards and recognition About Novartis is an innovative ...
Novartis Gene Therapies Medical Portal is committed to providing the most up‑to‑date, accurate, and balanced scientific information regarding its products.Please select the relevant below options to get accurate medical and scientific information....
Novartis Gene Therapies Manufacturing Quality Audit program Novartis quality management system (QMS) Product and patient safety training Regulatory inspections Product recalls Third-party suppliers Novartis and the European Union (EU) Awards and recognition About Novartis is an innovative ...
这一变化强调了基因治疗对诺华未来战略的重要性,同时也是为了摆脱去年AveXis申报Zolgensma时发生的数据操纵丑闻。 2018年4月,诺华以87亿美元收购了AveXis,获得了脊髓性肌萎缩症(SMA)基因治疗产品Zolgensma,从而使诺华成为新兴基因治疗领域的领跑者。 2018年7月,在Zolgensma获批上市两个月后,诺华报告FDA说,申请Zol...
The value of the scientific research produced by third party sponsors is key to complementing Novartis-sponsored research by helping us to better understand the benefit/risk profile of our therapies, as well as enabling us to explore new opportunities addressing unmet m...
据悉,这一更名变化强调了基因治疗对诺华未来战略的重要性,同时也是为了摆脱去年AveXis申报Zolgensma时发生的数据操纵丑闻。 2018年4月,诺华以87亿美元收购了AveXis,获得了脊髓性肌萎缩症(SMA)基因治疗产品Zolgensma,从而使诺华成为新兴基因...
Medical Officer, Novartis. “The totality of evidence clearly supports a positive risk benefit profile of OAV101 which is expected to support registration covering a broad range of SMA patients. We remain committed to leading innovation...
therapy-Novartis Gene Therapies; SMNT-gene-therapy-Novartis Gene Therapies; Spinal-muscular-atrophy-gene-therapy-Novartis Gene Therapies; Survival-motor-neuron-1-gene-therapy-Novartis Gene Therapies; T-BCD541-gene-therapy-Novartis Gene Therapies; Telomeric-SMN-gene-therapy-Novartis Gene Therapies; ZOL...